COVID-19 pharmacotherapy utilization patterns during pregnancy: International Registry of Coronavirus Exposure in PregnancyObservational Study Published on 2022-07-012022-10-04 Journal: Pharmacoepidemiology and drug safety [Category] COVID19(2023년), SARS, 임상, [키워드] antibody Anticoagulant chloroquine/hydroxychloroquine country COVID-19 COVID-19 patient COVID-19 test COVID-19 therapeutics COVID-19 treatment demographic characteristics drug drug utilization enrolled exposure finding Health include increased risk infected with SARS-CoV-2 information interferon International medications Mild moderate MOST Neonatal Observational cohort study Obstetric online questionnaire oseltamivir outcome outcomes participant pattern pharmacoepidemiology Pregnancy pregnant pregnant women Preterm birth registry Remdesivir reported repurposed therapy risk safety profile severe cases steroid Symptoms Therapies therapy treat with COVID-19 women [DOI] 10.1002/pds.5440 PMC 바로가기 [Article Type] Observational Study
Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variantsCorrespondence Published on 2022-07-012022-10-05 Journal: The Journal of Infection [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] antiviral drug antiviral therapy Aprotinin combination therapy COVID-19 interferon Interferon-beta molnupiravir Nirmatrelvir Remdesivir SARS-CoV-2 SARS-CoV-2 variant [DOI] 10.1016/j.jinf.2022.07.023 [Article Type] Correspondence
Prolonged fecal shedding of SARS-CoV-2 in a young immunocompetent COVID-19 patient: A case report and literature overview면역 능력이 있는 젊은 COVID-19 환자에서 SARS-CoV-2의 장기간 대변 배출: 증례 보고 및 문헌 개요Review Published on 2022-07-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Antiviral treatment Asymptomatic Case report coronavirus coronavirus disease Coronavirus disease 2019 Course COVID-19 COVID-19 pneumonia detection exhibited exposure to fecal glucocorticoid immunocompetent immunosuppressive therapies indicate interferon interferon therapy moderate Patient Pneumonia Prolonged prolonged viral RNA shedding. remained RNA SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus Stool stool samples the patient therapy throat swab throat swabs Viral RNA Viral RNA shedding Virological [DOI] 10.1002/jmv.27694 PMC 바로가기 [Article Type] Review
Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies질병 변형 요법으로 치료받는 다발성 경화증 환자에서 일반적인 3회 투여 일정에 따른 SARS-CoV-2 백신 접종에 대한 항체 반응Article Published on 2022-07-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] age anti-CD20 anti-CD20 treatment antibody benefit COVID-19 disease Disease modifying treatment dose dosing schedule fumarate humoral immune system immunization Immunocompromised interferon medication mRNA vaccination MS multiple sclerosis Part Patient patients patients treated retrospective SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 virus spike tested the vaccine therapy treated treated patients treatment with anti-CD20 vaccination Vaccine vaccine response [DOI] 10.1016/j.msard.2022.103856 PMC 바로가기 [Article Type] Article
Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trialRandomized Controlled Trial Published on 2022-07-012022-10-05 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 임상, [키워드] Adverse adverse event adverse events Antiviral Antiviral agents clinical Combination combination regimen combination therapy COVID-19 Day demonstrated Efficacy Efficacy and safety event examined Favipiravir FVP group groups hospital ICU admission ill patient in-hospital mortality incidence interferon Interferon-beta IQR LOS median Mild not different not significantly different Patient Potential treatment primary endpoint randomization Randomized randomized clinical trial Randomly receive Registered registry SARS-coronavirus SARS-CoV-2 Seven single-center Treatment treatment regimen Trial viral clearance [DOI] 10.1002/jmv.27724 PMC 바로가기 [Article Type] Randomized Controlled Trial
Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine – A Prospective Observational StudyBNT162b2 COVID-19 백신의 3차 접종에 대한 세포 및 체액 면역 반응 - 전향적 관찰 연구Observational Study Published on 2022-07-012022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] addition administration All participant All participants anti-SARS-CoV-2 antibody binding binding antibody blood sample Blood samples BNT162b2 booster booster dose cellular Cellular immune response Combination COVID-19 detectable dose evaluate health-care humoral humoral and cellular immunity Humoral immunity immune response Immunity immunological infection rate infection rates interferon Interferon-gamma median Neutralizing antibodies neutralizing antibody observational study of BNT162b2 participant peptide peptides prime-boost regimen Prospective prospective observational study protocols provided quantitative assay questionnaire Questionnaires real-world data response SARS-CoV-2 second dose Seroprevalence significant increase significantly third dose vaccination Vaccine was measured were measured [DOI] 10.3389/fimmu.2022.896151 PMC 바로가기 [Article Type] Observational Study
Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapyB세포 고갈 요법으로 치료받은 환자에서 BNT162b2 mRNA COVID-19 백신 3차 접종에 대한 체액 및 세포 반응 평가Article Published on 2022-07-012022-09-11 Journal: Journal of autoimmunity [Category] MERS, 바이오마커, 유전자 메커니즘, 진단, [키워드] affected anti-CD20 anti-S anti-SARS-CoV-2 antibody Autoimmune disease B-cell BNT162b2 CD-20 CD20 cellular immunity cellular response Cohort COVID-19 COVID-19 vaccination COVID-19 vaccine depleting dose doses drug group healthy control healthy controls humoral humoral and cellular immunity IFN-g IgG IMID Immune-mediated inflammatory disease Immune-mediated inflammatory diseases immunogenic immunogenicity Immunosuppressed immunosuppressed patient immunosuppressed patients Inflammatory diseases interferon mRNA mRNA COVID-19 vaccine mRNA COVID-19 vaccines naïve Neutralization assay neutralization assays neutralization titer neutralization titers Neutralizing antibodies neutralizing antibody no significant difference of BNT162b2 Patient patients treated Quantitative reduced response seroconverted significant difference significantly spike subject therapy These data treated vaccination [DOI] 10.1016/j.jaut.2022.102848 PMC 바로가기 [Article Type] Article
In Vitro Exposure of Primary Human T Cells and Monocytes to Polyclonal Stimuli Reveals a Basal Susceptibility to Display an Impaired Cellular Immune Response and Develop Severe COVID-19다클론 자극에 대한 1차 인간 T 세포 및 단핵구의 체외 노출은 손상된 세포 면역 반응을 표시하고 심각한 COVID-19를 발생시키는 기초 감수성을 나타냅니다Article Published on 2022-07-012022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 바이오마커, [키워드] (PD-1 acute respiratory syndrome acute respiratory syndrome coronavirus Alpha analyzed Anosmia anti-CD3 Antibody titer Antibody titers basal baseline characteristics biochemical blood sample Blood samples CD14 CD16 CD4+ CD8+ T cell CD8+ T cells Cellular immune response cellular immunity classical classical monocytes clinical recovery conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 progression disease display distress drug Evidence exposure expression Fever Follow-up headache healthy volunteer Human Humoral immunity hypoxia IFN-alpha IFN-gamma IL-2 immune function immune response Immunoglobulin Immunoglobulin G Impaired in vitro interferon interleukin interleukin-2 Invasive mechanical ventilation lipopolysaccharide Mild mild cases monocyte monocyte subsets Monocytes Neutralizing no difference no differences non-classical monocyte Non-classical monocytes not differ participant Patient PD-1 Pneumonia polyclonal predisposition programmed cell death programmed cell death protein prospective cohort study Protein receiving Registered required respiratory respiratory distress response S1 protein SARS-CoV-2 SARS-COV-2 infection serum titer Severe case severe cases severe COVID-19 severity significantly subset Symptom T cell T cells virus worsening [DOI] 10.3389/fimmu.2022.897995 PMC 바로가기 [Article Type] Article
Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severityCOVID-19 환자의 항-IFN-α/-ω 중화 항체는 IFN 반응의 하향조절 및 질병 중증도의 실험실 바이오마커와 상관관계가 있습니다Article Published on 2022-07-012022-09-11 Journal: European Journal of Immunology [Category] MERS, 바이오마커, 진단, 치료기술, [키워드] Antiviral association autoantibodies autoantibodies, SARS-CoV-2 binding binding antibodies binding antibody biochemical characterized COVID-19 COVID-19 patient cross-reactivity CRP D-dimer dimer disease severity downregulation fluctuation Gene Expression hematological parameters ICU IFN IFN response IFN-stimulated gene IFN-stimulated genes IFN-α interferon ISG ISGs laboratory biomarker laboratory biomarkers LDH male Neutralizing antibodies neutralizing antibody outcome Patient patients positive positive patient proportion quantified reduced respiratory Respiratory samples screened sera serum severe COVID-19 shown specificity subset tested transcript levels [DOI] 10.1002/eji.202249824 PMC 바로가기 [Article Type] Article
Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patientsMS 환자에서 SARS-CoV-2 백신 접종 후 체액 및 세포 면역 반응에 대한 질병 수정 요법의 영향Article Published on 2022-07-012022-09-12 Journal: Clinical and translational science [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] benefit cellular Cellular immune response humoral humoral immune response Impact individual Infection interferon interferon beta investigated multiple sclerosis Patient patients pre-vaccination receiving reduced robust SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 vaccination therapy Treatment vaccination vaccination efficacy [DOI] 10.1111/cts.13256 PMC 바로가기 [Article Type] Article